Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, N C, Scarlett, C J, Kench, J G, Sum, E Y M, Segara, D, Colvin, E K, Susanto, J, Cosman, P H, Lee, C-S, Musgrove, E A, Sutherland, R L, Lindeman, G J, Henshall, S M, Visvader, J E, Biankin, A V
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2243155/
https://www.ncbi.nlm.nih.gov/pubmed/18231110
http://dx.doi.org/10.1038/sj.bjc.6604177
Descripción
Sumario:Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.

Ejemplares similares